Management of Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis

Abstract The survival of idiopathic pulmonary fibrosis (IPF) (a deadly respiratory condition) in patients with pulmonary hypertension (PH) is very low. Particularly, people having chronic lung parenchymal conditions who also have pulmonic vascular disorder experience worse outcomes than those who only have those diagnoses. This holds for the course of these diseases naturally, the results of medicinal treatments, and even the results of lung transplantation. PH in IPF patients is linked to a worse prognosis and a diminished capacity for activity. It is crucial to look at PH in these patients due to its prognostic relevance. Therefore, there is an urgent need for better PH treatments in the context of IPF. Based on the molecules that cause pulmonary fibrosis and narrowing of blood vessels/structural changes in blood vessels, we analyze possible targets for pharmacotherapy in the future and give an overview of current treatments in this review.